Combination therapy for liver cancer that can be surgically removed
Part of Cancer clinical trials.
This trial tests a combination of three treatments—chemo given directly into the liver, an oral targeted therapy, and an immunotherapy—for people with liver cancer that could be removed by surgery but isn't the first choice right now. The goal is to see if this combination can shrink the tumor and improve outcomes before surgery.
Summary written for real people, not researchers, by Clin2.
Who can take part
- You are 18 years or older.
- You have been diagnosed with hepatocellular carcinoma (a type of liver cancer) that has not spread to other parts of the body.
- Your liver cancer is considered potentially removable by surgery, but surgery is not the first choice right now (for example, the tumor is large or involves certain blood vessels).
- You have not been previously treated with a PD-1 inhibitor (a type of immunotherapy) or lenvatinib (a targeted therapy).
- You are generally in good health, with a performance status of 0 or 1 (able to do daily activities without major help).
- Your liver function is adequate (Child-Pugh score of 7 or less, and no severe cirrhosis).
Quick eligibility check
Answer a few plain-language questions, based on this study's own requirements, to get a preliminary sense of fit.
Similar studies
Other trials that look related to this one.
This trial combines an immunotherapy (Envafolimab), a targeted therapy (Suvemcitug), and a special chemotherapy infusion that goes directly into the liver (HAIC) to try to shrink or control advanced liver cancer that can't be removed by surgery. The goal is to help convert the tumor to a state where it might be operable, and to improve long-term outcomes.
This trial tests a combination of immunotherapy (camrelizumab), a targeted drug (rivoceranib), and liver-directed chemotherapy (HAIC) to shrink liver tumors enough to make them removable with surgery. It is for people with intermediate or advanced liver cancer that has not spread outside the liver.
This study tests a combination of three treatments (HAIC, lenvatinib, and cadonilimab) as a way to shrink liver tumors that cannot be removed with surgery. The goal is to make the tumors smaller so they might be removed later, and to see how safe and effective this combination is.
This trial tests a combination of a procedure that delivers chemotherapy directly to the liver tumor (called TACE) with an oral targeted therapy drug (lenvatinib) for people with liver cancer that cannot be removed with surgery. The goal is to see if this combination can shrink tumors more effectively than TACE alone.
This trial tests a combination of two immunotherapy drugs (iparomlimab and tuvonralimab) plus lenvatinib (a targeted therapy) given before surgery for hepatocellular carcinoma (a type of liver cancer). The goal is to see if this treatment can shrink tumors and reduce the chance of cancer coming back after surgery.
This trial tests a combination treatment for advanced liver cancer that cannot be removed with surgery. It combines a procedure (irreversible electroporation) that uses electrical pulses to destroy cancer cells, with targeted therapy (lenvatinib) and immunotherapy (sintilimab) to help your immune system fight the cancer.
Hear when a new Potentially Resectable Hepatocellular Carcinoma trial opens
We’ll email you when one opens — at most once a week, no account needed, unsubscribe anytime.